Business Context and Reporting Period
Company: DaVita Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and nine months ended September 30, 2004
Business Overview: DaVita is a leading provider of dialysis services. The company operates a network of dialysis centers and provides related services, including laboratory testing and pharmaceutical administration. As of November 1, 2004, approximately 97.6 million shares of common stock were outstanding.
Key Financial Metrics
(All figures in thousands, except per share data)
| Metric | Q3 2004 | Q3 2003 | 9 Months 2004 | 9 Months 2003 |
|---|---|---|---|---|
| Net Operating Revenues | $595,531 | $513,282 | $1,682,592 | $1,462,972 |
| Operating Income | $111,652 | $95,211 | $304,952 | $257,345 |
| Net Income | $60,386 | $38,060 | $165,652 | $112,993 |
| Diluted EPS | $0.59 | $0.36 | $1.61 | $1.07 |
| Cash from Operations (9mo) | $332,604 (vs. $259,072 in 2003) | |||
| Cash and Equivalents (Sep 30, 2004) | $226,942 | |||
| Total Debt (Sep 30, 2004) | $1,387,964 (Current: $53,277; Long-term: $1,334,687) |
Operational Highlights:
- Dialysis treatments increased to 1,804,534 in Q3 2004 (vs. 1,625,058 in Q3 2003).
- Average dialysis revenue per treatment rose to $314 (vs. $306 in Q3 2003).
- Patient care costs remained stable at approximately 68% of current period revenues.
Material Changes vs. Prior Period
- Revenue Growth: Net operating revenues increased 16% year-over-year for the nine months ended September 30, 2004. This was driven by a 11% increase in treatment volume and a 3% increase in average reimbursement rates, alongside $8.3 million in prior-year Medicare lab recoveries recognized in Q3.
- Profitability: Net income for the nine months increased 47% to $165.7 million, primarily due to revenue growth and lower debt expense ($36.6 million vs. $55.1 million in the prior year period).
- Acquisitions: The company completed 16 acquisitions totaling approximately $246.5 million, including the purchase of Physicians Dialysis Inc. (PDI) for $150 million effective September 1, 2004.
- Debt Structure: On July 30, 2004, the company amended credit facilities, extending Term Loan B maturity to 2010 and adding a new $250 million Term Loan C. Total debt increased significantly to fund acquisitions and share repurchases.
- Stock Split: A three-for-two stock split was executed in June 2004; all share data has been restated.
Guidance, Outlook, and Risks
Outlook and Guidance
- Q4 2004: Management expects operating income to be comparable to Q3 2004.
- 2005 Outlook: Operating income is expected to be flat to 6% higher than 2004 levels. This projection accounts for potential negative impacts from the 2003 Medicare Modernization Act (MMA), specifically proposed changes to EPO utilization and case-mix adjustments.
- Share Repurchases: The Board authorized an additional $200 million in repurchases in November 2004, bringing total authorization to approximately $250 million.
Risks and Contingencies
- Government Investigations: The company is cooperating with a subpoena from the U.S. Department of Justice (Eastern District of New York) regarding operations, laboratory services, and physician relationships. A separate, ongoing review by the U.S. Attorney's Office in Philadelphia continues. Penalties could be substantial if wrongdoing is found.
- Medicare Lab Recoveries: A Florida-based laboratory subsidiary has been under review since 1998. While recent rulings recovered $8.3 million in Q3, less than $4 million in disputed billings remain. Future reimbursement rates and audit methodologies remain uncertain.
- Reimbursement Rates: Approximately 40% of revenue comes from private payors and 50% from Medicare. Declines in private rates or changes in Medicare composite rates (including the 2005 case-mix adjustment) could materially reduce earnings.
- Pharmaceutical Costs: EPO administration accounts for roughly one-third of revenues. Price increases by the sole supplier (Amgen) or shifts to alternative drugs (e.g., Aranesp) could impact margins.
Investor Verification Checklist
- Regulatory Exposure: Verify the status and potential financial impact of the DOJ subpoena and the Philadelphia OIG investigation.
- Medicare Lab Resolution: Confirm the final resolution of the Florida laboratory dispute and the timeline for the remaining $4 million in disputed billings.
- 2005 Reimbursement Impact: Assess the specific financial modeling regarding the CMS case-mix adjustment and EPO utilization changes effective in 2005.
- Debt Covenants: Review the amended credit facility terms, specifically the restricted payment covenants related to acquisitions and the maturity profile of the new Term Loan C.
- Acquisition Integration: Monitor the integration of Physicians Dialysis Inc. (PDI) and the finalization of purchase price allocations.